Assignee
CRINETICS PHARMACEUTICALS INC
US·31 granted patents·22 pending applications·128 citations·filing 2016–2025
Top patents by PatentIndex Score
53 records- 0197US10981894B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2020·Granted Apr 20, 2021·6 cites·20 claims
- 0296US11186590B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2020·Granted Nov 30, 2021·6 cites·11 claims
- 0395US11834462B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2022·Granted Dec 5, 2023·2 cites·16 claims
- 0495US10766877B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Sep 8, 2020·7 cites·20 claims
- 0595US10604507B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Mar 31, 2020·7 cites·20 claims
- 0695US10562884B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Feb 18, 2020·7 cites·20 claims
- 0794US11566015B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2021·Granted Jan 31, 2023·2 cites·36 claims
- 0894US11479540B2Nonpeptide somatostatin type 5 receptor agonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2020·Granted Oct 25, 2022·5 cites·43 claims
- 0993US12134610B2Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2024·Granted Nov 5, 2024·1 cites·29 claims
- 1093US10875839B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Dec 29, 2020·5 cites·10 claims
- 1193US10696689B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Jun 30, 2020·12 cites·8 claims
- 1293US9896432B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2017·Granted Feb 20, 2018·11 cites·20 claims
- 1392US10597377B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Mar 24, 2020·8 cites·9 claims
- 1492US10351547B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2017·Granted Jul 16, 2019·9 cites·24 claims
- 1592US9902703B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2016·Granted Feb 27, 2018·8 cites·17 claims
- 1691US11414397B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2020·Granted Aug 16, 2022·2 cites·23 claims
- 1791US11072598B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Jul 27, 2021·6 cites·20 claims
- 1891US9957267B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2016·Granted May 1, 2018·8 cites·22 claims
- 1990US2026055082A1Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2088US12479828B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2023·Granted Nov 25, 2025·0 cites·22 claims
- 2188US11266641B1Formulations of a somatostatin modulatorCRINETICS PHARMACEUTICALS INC·Filed 2021·Granted Mar 8, 2022·4 cites·30 claims
- 2285US10464918B2Process of making somatostatin modulatorsCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Nov 5, 2019·6 cites·24 claims
- 2385US2024109866A1Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2483US10889561B2Process of making somatostatin modulatorsCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Jan 12, 2021·3 cites·10 claims
- 2582US2026008767A1Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2680US11773076B2Crystalline forms of a somatostatin modulatorCRINETICS PHARMACEUTICALS INC·Filed 2022·Granted Oct 3, 2023·1 cites·29 claims
- 2780US11608335B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Mar 21, 2023·2 cites·21 claims
- 2880US2022380337A1Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2974US2024376067A1Process of making somatostatin modulatorsCRINETICS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3074US2022048924A1Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3174US2024254106A1Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3273US2024398782A1Formulations of a somatostatin modulatorCRINETICS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3369US11957674B2Formulations of a somatostatin modulatorCRINETICS PHARMACEUTICALS INC·Filed 2022·Granted Apr 16, 2024·0 cites·15 claims
- 3467US12208092B2Compositions and methods for administering paltusotine to patients with hepatic impairmentCRINETICS PHARMACEUTICALS INC·Filed 2024·Granted Jan 28, 2025·0 cites·27 claims
- 3567US2024285628A1Non-peptide targeted therapeutics and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3667US2024408247A1Non-peptide targeted therapeutics and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3766US2022144802A1Nonpeptide somatostatin type 5 receptor agonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3865US2024208963A1Crystalline melanocortin subtype-2 receptor (mc2r) antagonistCRINETICS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3964US2021087165A1Process of making somatostatin modulatorsCRINETICS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4064US2024366587A1Uses of a somatostatin modulator for the treatment of diseaseCRINETICS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 4163US2025312331A1Compositions and methods for administering paltusotine to patients with hepatic impairmentCRINETICS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 4260US2023159532A1Parathyroid hormone (pth) receptor antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4357US2022387420A1Uses of a somatostatin modulator for the treatment of diseaseCRINETICS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4454US12492181B2Gem-disubstituted piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2020·Granted Dec 9, 2025·0 cites·21 claims
- 4554US2026007758A1Somatostatin subtype-2 receptor (sst2r) non-peptide drug conjugates and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 4653US12479825B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2020·Granted Nov 25, 2025·0 cites·19 claims
- 4753US12466829B2Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2020·Granted Nov 11, 2025·0 cites·19 claims
- 4853US12280046B2Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of diseaseCRINETICS PHARMACEUTICALS INC·Filed 2022·Granted Apr 22, 2025·0 cites·18 claims
- 4945US2025367190A1Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of diseaseCRINETICS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 5044US2022267295A1Crystalline forms of somatostatin modulatorsCRINETICS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
Showing the top 50 of 53 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →